HEPATOCELLULAR CARCINOMA: Interpreting the Evidence to Improve Clinical Outcomes
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide, and rates are increasing each year. The majority of HCC is diagnosed in advanced stages, where potentially curative therapy is ineffective, and outcomes are poor. In recent years, several targeted therapies and immunotherapies have emerged that have drastically changed outcomes in advanced HCC.
This program will cover current and emerging treatment options for advanced HCC, how to make patient-personalized treatment decisions, and how to manage treatment emergent adverse events to ensure optimal outcomes.
The intended audiences for this educational initiative include all members of the multidisciplinary team involved in the management of patients with HCC, including community oncologists, surgeons, interventional radiologists, radiation oncologists, and hepatologists.
The proposed initiative is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this education, participants should be able to:
- Recognize that the mortality rate for HCC patients is excessively high, and adjust clinical practice decisions accordingly
- Evaluate and implement management strategies to include use of newer therapies in HCC patients who would benefit from such agents
- Translate emerging clinical science to clinical practice in patients with HCC
- Discuss clinical evidence that supports guideline recommendations for the management of adverse events associated with novel therapies for HCC
Richard S. Finn, MD
Department of Medicine
Division of Hematology/ Oncology
UCLA David Geffen School of Medicine
Director, Signal Transduction and Therapeutics Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, CA
Richard S. Finn, MD is a Professor of Clinical Medicine in the Division of Hematology/ Oncology at the UCLA David Geffen School of Medicine and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA. He currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer. Dr Finn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. His work has been published in journals such as the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Clinical Cancer Research, Hepatology, Cancer Cell and elsewhere. Dr Finn has also given oral presentations at major meetings including American Society of Clinical Oncology (ASCO), European Cancer Conference (ECCO/ ESMO), and the American Association of Cancer Research (AACR) and others. An active cancer researcher, he has been involved in the development of several novel therapeutics in cancer medicine. He has brought several practice changing advanced to cancer medicine. He led the approval of palbociclib (Ibrance), the first CDK 4/6 inhibitor in cancer medicine, from pre-clinical development to global registration and more recently the combination of atezolizumab and bevacizumab in liver cancer.
Dr. Finn is a member of ASCO, American Association of Cancer Research (AACR) and the European Society of Medical Oncology (ESMO). He is a past president of the International Liver Cancer Association (ILCA). He is on the editorial board of Clinical Cancer Research.
Amit Singal, MD, MS
Professor of Medicine
Chief of Hepatology and Medical Director, Liver Tumor Program
UT Southwestern Medical Center
Amit Singal, MD, MS is a Professor of Medicine and Chief of Hepatology at UT Southwestern Medical Center in Dallas, TX. He is an expert in hepatocellular carcinoma and serves as the Medical Director of the UT Southwestern Liver Tumor Program. Dr Singal is board certified in gastroenterology and transplant hepatology, with his research focusing on diagnosing and treating liver cancer at an early stage. He has received numerous grants, including from the National Institutes of Health (NIH), Cancer Prevention Research Institute of Texas (CPRIT), and the Department of Defense, and he lectures on his work frequently throughout the world. Dr. Singal is a member of multiple professional organizations, including the American Gastroenterological Association, the American College of Gastroenterology, and the American Association for the Study of Liver Diseases, and he serves on the International Liver Cancer Association’s Executive Committee. He is also on the editorial board for several journals including an Associate Editor for Clinical Gastroenterology and Hepatology. Dr. Singal has published over 200 scientific papers regarding HCC screening and treatment. For his work, he has been awarded the David Bruton Professorship in Clinical Cancer Research and Blue Faery Award for Excellence in Liver Cancer Research.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The faculty, authors and content developers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Richard S. Finn, MD: Consultant/Independent Contractor: AstraZeneca, Bayer, Bristol Myers Squibb, CStone, Eisai, Eli Lilly, Genentech, Merck, Pfizer, Roche; Grant/Research Support: Adaptimmune, Bristol Myers Squibb, Eisai, Eli Lilly, Genentech, Merck, Pfizer, Roche
Amit Singal, MD, MS: Consultant/Independent Contractor: AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Exact Sciences, Genentech, Glycotest, GRAIL, Roche, Wako Diagnostics
Planners and Managers
The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chelsey Goins, PhD: Nothing to disclose
The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Katie Propst, PhD: Nothing to disclose
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email [email protected].
- 1.00 AMA PRA Category 1 Credit™
This course is offered through Rockpointe.
To take this course you will be redirected to Rockpointe's website. You must login or create an account with Rockpointe in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!